[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"urothelial-carcinoma-of-the-renal-pelvis-and-ureter\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:urothelial-carcinoma-of-the-renal-pelvis-and-ureter":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,74,107,133,188,204],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100578964","bladder-epicheck-european-haematuria-study-100578964",false,"NCT06818136","Bladder EpiCheck European Haematuria Study","Evaluation of the Efficacy of Bladder EpiCheck® for the Primary Detection of Urothelial Carcinoma in Subjects Presenting With Haematuria","Inclusion Criteria:\n\n1. Participants aged 45 years or older\n2. Participants who are willing and able to provide written informed consent and adhere to study procedures\n3. Participants presenting with visible and\u002For non-visible haematuria within 6 months prior to study enrollment\n4. Participants scheduled to undergo standard of care cystoscopy for urinary bladder examination within 60 days after study enrollment\n5. Participants who are able to produce at least 10 ml of voided urine\n\nExclusion Criteria:\n\n1. Participants with history of urothelial cancer in the bladder and\u002For upper urinary tract\n2. Participants who had prior cystoscopy for haematuria within the past 2 years\n3. Participants previously enrolled in this study\n4. Participants treated for prostate cancer within the last 12 months\n5. Participants treated for kidney cancer within the last 12 months\n6. Participants with untreated urinary tract infection\n7. Participants with symptomatic urinary tract stones (e.g. flank pain)\n8. Participants on dialysis for end stage renal failure\n9. Participants with a long term urinary catheter\n10. Pregnancy (self-reported)\n11. Participants who, because of medical status, or frailty is not expected to be able to complete the full diagnostic pathway","ALL","45 Years",{"count":19,"type":20},800,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to further validate the sensitivity and specificity of Bladder EpiCheck in primary detection of urothelial carcinoma in participants aged 45 years or older presenting with haematuria, compared to cystoscopy and pathology, if performed.\n\nParticipants will provide a voided urine sample, and data from standard of care haematuria work-up will be collected.",[24,25,26,27,28],"Hematuria","Cystoscopy","Urothelial Carcinoma Bladder","Urothelial Carcinoma of the Renal Pelvis and Ureter","Urothelial Carcinoma of the Urinary Bladder",[30,31,32],"urine test","methylation","primary detection","RECRUITING","2026-01-21",{"date":36,"type":37},"2026-01-22","ACTUAL",{"date":39,"type":37},"2025-06-20",{"date":41,"type":20},"2026-12",{"name":43,"class":44},"Nucleix Ltd.","INDUSTRY",5,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100525687","phase-2-multicenter-clinical-trial-of-st-02-for-ablation-of-upper-tract-urothelial-carcinoma-100525687","NCT06124976","Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial Carcinoma","A Phase 2\u002F3 Multicenter Trial Evaluating the Safety and Efficacy of ST-02 (Mucoadhesive Gemcitabine Suspension) on Ablation of Urothelial Carcinomas in the Upper Urinary Tract","Inclusion Criteria:\n\n* Adult (≥ 18 years) male or female\n* Primary or recurrent low-grade (LG), noninvasive (Ta) Upper Tract Urothelial Carcinoma (UTUC) in the renal pelvis, infundibulum, and\u002For calyces, based on ureteroscopy, biopsy and cytology performed within 8 weeks prior to the Screening Visit\n* At least 1 measurable papillary tumor measuring 5-15 mm\n* Low grade tumor(s) in the ipsilateral ureter. Every attempt should be made to ablate this tumor completely, but residual ipsilateral ureteral tumor is not an exclusion criterion.\n* Prior fully ablated low grade bladder tumor(s), without the need for intravesical therapy except for single-dose chemotherapy\n* A life expectancy of greater than 12 months\n* No active untreated urinary tract infection (UTI) as confirmed by urine culture or urinalysis\n* Women of Child bearing potential (WoCBP) and Males who have a WoCBP partner require a negative pregnancy test at the Screening visit and must use two acceptable contraceptives methods until six months post-treatment\n* All sexually active males must agree to use a condom during intercourse, for at least 48 h after each instillation\n\nExclusion Criteria:\n\n* Have received Bacillus Calmette - Guerin (BCG) treatment for UTUC within 6 weeks prior to Visit 1\n* Pregnant (positive urine pregnancy test), planning pregnancy during trial, breast-feeding, or of childbearing potential without reliable contraception\n* Unresolved infection requiring active treatment with systemic antimicrobial drugs\n* History of high-grade non-muscle invasive bladder cancer within the past 6 months\n* History of muscle-invasive bladder cancer during the past 2 years\n* Actively being treated or intend to be treated with intravesical or systemic chemotherapy during the duration of the trial\n* Urinary obstruction in the ipsilateral Upper Urinary Tract (UUT)\n* Any contraindicated to gemcitabine or sensitivity to gemcitabine or any of the ST-02 ingredients\n* Currently receiving another investigational agent or involved in a clinical trial with an investigational product within the past 30 days prior to Visit 1\n* Active hepatitis B (chronic or acute) or active hepatitis C infection","18 Years",{"count":55,"type":20},70,"INTERVENTIONAL",[58,59],"PHASE2","PHASE3","The goal of this prospective clinical trial is to investigate the safety and efficacy of ST-02 (mucoadhesive gemcitabine suspension for pyelocaliceal instillation) to treat Upper Tract Urothelial Carcinoma (UTUC) in participants who have a low-grade tumor.\n\nThe main questions this study aims to answer are:\n\n1. Can ST-02 effectively eradicate UTUC by 3 months?\n2. Is ST-02 safe for patients with UTUC?\n\nParticipants in this study will receive ST-02, a new formulation with gemcitabine once weekly for six weeks. Gemcitabine is known to be an effective drug in treating urothelial carcinoma. This new formulation will be instilled directly into the upper urinary tract (renal pelvis) and will allow the chemotherapeutic to work locally for an extended period of time. The administration process will be retrograde (via a small catheter inserted up into the kidney, under anesthesia) or antegrade (via a nephrostomy, in the clinic) once weekly for six weeks. Safety and efficacy will be monitored for up to a year after the initial response assessment.",[27,62],"Transitional Cell Cancer of the Renal Pelvis and Ureter","2025-09-08",{"date":65,"type":37},"2025-09-15",{"date":67,"type":37},"2024-06-19",{"date":69,"type":20},"2026-04",{"name":71,"class":72},"University of British Columbia","OTHER",4,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":56,"phases":85,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":106},"100591652","phase-2-clinical-trial-of-am80-in-combination-with-gemcitabine-cisplatin-and-nivolumab-in-patients-with-urothelial-carcinoma-100591652","NCT06983210","Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma","Multi-center, Open-Label, Single Arm Trial for Evaluation of the Efficacy and Safety in the First Line Combination Therapy of Gemcitabine, Cisplatin and Nivolumab With Additional Pretreatment of AM80 for Urothelial Carcinoma Patients","GRAPE","Inclusion Criteria:\n\n1. Patients who have been histologically or cytologically diagnosed with urothelial carcinoma of the renal pelvis, ureter, bladder, or urethra based on the General Rule for Clinical and Pathological Studies on Renal Pelvic, Ureteral and Bladder Cancer, 2nd Edition that cannot be curatively resected or has recurred (diagnosis is not permitted at the site of palliative radiation)\n2. Patients who have not received prior treatment for unresectable or recurrent urothelial carcinoma\n3. Patients with measurable lesions according to RECIST version 1.1 on the CT at screening\n4. Patients with an ECOG PS of 0-1 at screening, who are able to take oral medication\n5. Patients who will be expected to survive for 12 weeks or more from the enrollment\n6. Patients whose major organ functions at screening meet the following criteria\n\n(1)Neutrophil count: 1,500\u002FuL or more (2)Platelet count: 100,000\u002FuL or more (3)Hb: 9.0 g\u002FdL or more (no red blood cell transfusion within 14 days prior to screening examination) (4)T-Bil: 1.5 times or less than 1.5 times the upper limit of the facility standard value (less than 3.0 mg\u002FdL in the case of Gilbert syndrome) (5)AST and ALT: 3 times or less than 3 times the upper limit of the facility standard value (6)CrCl 50 mL\u002Fmin or more 7.Patients who have given consent to be treated if any of the following applies:\n\n1. Female patients of childbearing potential who can prevent contraception for 30 days prior to enrollment and for 2 years after the end of AM80 treatment\n2. Male patients with partners of childbearing potential, who can use contraception from the start of AM80 administration until 7 months after the end of administration and refrain from donating sperm during the above period 8.Patients aged 18-79 years at the time of consent (regardless of sex) 9.Patients who have received a thorough explanation of this clinical trial and have voluntarily given their written informed consent\n\nExclusion Criteria:\n\n1. Patients who have previously been treated with drugs such as antibodies targeting PD-1, PD-L1, PD-L2, CTLA-4, OX-40, or CD137\n2. Patients who have received any of the following t reatments for urothelial carcinoma:\n\n(1)Perioperative adjuvant therapy for curative resection completed less than 12 months prior to enrollment (2)Intravesical therapy within 28 days prior to enrollment (3)Palliative radiation therapy for measurable lesions within 14 days prior to enrollment 3.Patients who have not recovered from toxicity (Grade 1 or 0 or at baseline) from prior treatment at the time of enrollment; however, enrollment is permitted for those with \\\u003C= Grade 2 fatigue and alopecia 4.Patients who have participated in other clinical trials within 28 days prior to enrollment (enrollment is permitted if the drug or medical device used in the clinical trial are similar to approved indications, dosage, and administration and do not affect the evalu ation) and who have received their last dose of a drug or other substance used in the current clinical research within the last 28 days 5.Patients with metastasis to the central nervous system or a history or complication of carcinomatous meningitis 6.Patients with multiple cancers whose disease-free interval at the time of registration is less than 3 years (excluding gastrointestinal cancer that was completely resected via endoscopic mucosal resection, completely resected intraepithelial neoplasia of the cervix, localized or presumably cured prostate cancer, completely resected basal\u002Fsquamous cell carcinoma of the skin, and solid cancers similar to these that have undergone curative treatment and are presumed to be cured) 7.Patients who are taking vitamin A agents or vitam in A-containing supplements at the time of enrollment 8.Patients who have undergone surgery under general anesthesia (excluding diagnostic biopsies) or severe trauma within 28 days prior to enrollment 9.Patients known to have a bleeding tendency or coagulation disorder (e.g., patients with significant in tratumoral bleeding, thromboembolism, or a history or comorbidity of bleeding disorders), and those who require administration of anticoagulants or antiplatelet drugs 10.Patients with active infections requiring systemic administration of antibiotics, antifungals, or antivirals 11.Patients who test positive for hepatitis B surface (HBs) antigen, hepatitis C virus (HCV) antibody and RNA, or HIV antigen or antibody. However, even if the patient is negative to HBs antigen, if the patient is positive to HBs antibody or hepatitis B core (HBc) antibody, the possibility of inclusion should be considered in consultation with a gastroenterologist, if necessary, based on Document 3 of the latest Hepatitis B Treatment Guidelines.\n\n12.Patients with a history of or comorbidity of interstitial lung disease evident on imaging, or those with active non-infectious pneumonitis 13.Patients with autoimmune disease, a history of chronic or recurrent autoimmune disease, or those who have required high-dose systemic corticosteroids (prednisolone equivalent of more than 10 mg\u002Fday) or immunosuppressants within 14 days prior to enrollment 14.Patients who require treatment for tuberculosis 15.Patients with clinical symptoms or findings indicating intestinal obstruction requiring intravenous or total parenteral nutrition, and those with risk factors for intestinal perforation (e.g., acute diverticulitis, in traperitoneal abscess, gastrointestinal obstruction, history of abdominal tumor, etc.).\n\n16.Patients with gastrointestinal disorders that may affect the absorption of AM80 17.Patients with a history of severe hypersensitivity or anaphylactic reactions to components of the drugs used in the clinical trial or antibody preparations 18.Patients who received live or attenuated vaccines within 30 days prior to enrollment 19.Patients with serious complications (liver disease , kidney disease, heart disease, lung disease, blood disease, brain disease, etc.) 20.Patients with uncontrolled adrenal insufficiency, Grade 2 or higher hearing impairment, or Grade 2 or higher neuropathy 21.Patients with hypervitaminosis A 22.Lactating female patients (excluding those who agreed to discontinue breastfeeding during the study period and for 6 months after the final dose of A M80) 23.Female patients who are pregnant or have positive pregnancy test results (female patients who have had a period within 12 months prior to enrollment and may be pregnant will be subjected to a pregnancy test. Female patients who have not had a period within 12 months but whose pregnancy cannot be ruled out due to reasons such as chemical menopause will also be subjected to a pregnancy test) 24.Patients who are otherwise deemed inappropriate for participation in this clinical trial by the principal investigator or sub-investigator","79 Years",{"count":84,"type":20},43,[58],"【Treatment of Urothelial Carcinoma】 Treatment for urothelial carcinoma includes surgery, chemotherapy (anticancer drugs), and radiation therapy. Chemotherapy is generally used when metastasis has already occurred at diagnosis and surgery is not curative (metastatic urothelial carcinoma) or when the cancer recurs after local therapy such as surgery or radiation therapy (recurrent urothelial carcinoma).\n\nAlthough there are several recommended treatments for urothelial carcinoma, the options are often limited by side effects and other factors, and these treatments may not be fully effective. Therefore, the development of safer and more effective treatments is desired.\n\n【About the Drugs to be Used in this Clinical Trial】 In this clinical trial, the investigational drug MIKE-1 will be used in combination with nivolumab plus GC (cisplatin gemcitabine), one of the recommended chemotherapy regimens, and subsequently with nivolumab monotherapy for patients with unresectable metastatic or recurrent urothelial cancer. Nivolumab, cisplatin, and gemcitabine are injectable (intravenous infusion), while MIKE-1 is oral.\n\n【Purpose of the Clinical Trial】 The purpose of this clinical trial is to evaluate the efficacy (how much the cancer shrinks or slows down) and safety of the investigational drug MIKE-1 in combination with nivolumab and gemcitabine and cisplatin therapy in patients with untreated unresectable or recurrent urothelial cancer.",[26,27,88,89],"Urothelial Carcinoma Urethra","Urothelial Carcinoma Recurrent",[91,92,93,94,95,96],"urothelial carcinoma","Gemcitabine, Cisplatin and Nivolumab","bladder cancer","renal pelvis cancer","ureteral cancer","urethral cancer","2025-08-09",{"date":99,"type":37},"2025-08-14",{"date":101,"type":37},"2025-05-01",{"date":103,"type":20},"2029-03-01",{"name":105,"class":72},"Nagoya University",1,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":56,"phases":117,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":132},"100579371","phase-2-9mw2821--toripalimab-vs-9mw2821-for-1st-line-locally-advanced-or-metastatic-urothelial-carcinoma-100579371","NCT06823427","9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma","A Randomized Phase II Trial to Evaluate 9MW2821 in Combination With Toripalimab Compared With 9MW2821 Monotherapy for the 1st Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma","Inclusion Criteria:\n\n* Voluntary participation\n* Age 18-80\n* ECOG 0-1\n* Histologically confirmed inoperable locally advanced or metastatic urothelial carcinoma (including bladder, renal pelvis and ureter). Mixed histology with squamous or adenomatous differentiation is allowed if urothelial carcinoma differentiation is \\>50%.\n* Has not received any systemic treatment for locally advanced or metastatic urothelial carcinoma\n* At least 1 measurable target lesion that satisfies RECIST v1.1 definition. If the patient has received radiotherapy, the target lesion needs to be outside the radiation field or has demonstrated clear progression after radiotherapy.\n* Life expectancy over 12 weeks\n* Appropriate hematological and organ functions\n* Agree to contraceptive measures until 180 days after the last dose of study drug administration\n* Able to understand and follow study visits, treatment, laboratory assessment and other procedures\n\nExclusion Criteria:\n\n* Other concurrent malignancy within 3 years prior to randomization\n* Active autoimmune disease requiring systemic treatment within 2 years prior to randomization. Having received high dose corticosteroid (\\>10mg\u002Fday prednisolone equivalent) or other immunosuppressive agents.\n* Severe cardiovascular or cerebral vascular thrombo-embolic events within 6 months prior to randomization\n* Major surgery within 28 days prior to randomization, except for minor procedures that the PI considers not to impact study participation. Live vaccine within 28 days prior to randomization or planning to take live vaccine during the study. Radiotherapy or bladder infusion therapy within 21 days prior to randomization. Use of strong CYP3A4 inhibitors within 14 days prior to randomization.\n* Lung effusion or ascites that require treatment within 14 days prior to randomization. Cancer-related severe uncontrolled bone pain or spinal cord compression within 14 days prior to randomization. Active infection that requires systemic antibiotic treatment within 7 days prior to randomization.\n* Have received prior treatment with anti-PD-1, anti-PD-L1\u002FPD-L2 or anti-CTLA-4 therapies. Have received prior treatment with Nectin-4 targeted therapy or ADC with MMAE as payload. Have received allogeneic hematological stem cell transplantation or solid organ transplant.\n* Toxicities from previous cancer treatment (radiotherapy, chemotherapy or surgery) that have not recovered to grade 0-1 according to CTCAE v5.0, except for alopecia and skin hyperpigmentation.\n* Severe dry eyes, active keratitis, corneal ulceration or other risk factors for corneal diseases where the PI judges to be not suited for this study\n* Preexisting grade ≥ 2 neuropathy prior to randomization\n* Other uncontrolled serious illness\n* Brain metastasis or meningeal carcinomatosis\n* HBsAg positive, and HBV-DNA copy number positive ; HCV-Ab positive and HCV-RNA positive; HIV-Ab positive\n* Known allergy to the study drug or components of the study drug\n* Drug abuse or psychiatric disorder that would impact study compliance\n* Other circumstances that the PI judges to be not suitable for the study","80 Years",{"count":116,"type":20},60,[58],"This study will compare the efficacy of 9MW2821+toripalimab versus 9MW2821 monotherapy in locally advanced or metastatic urothelial carcinoma patients who have not received any systemic treatment in the metastatic or advanced setting.",[120,26,89,27],"Urothelial Carcinoma",[122],"9MW2821","2025-03-20",{"date":125,"type":37},"2025-03-21",{"date":127,"type":37},"2025-01-17",{"date":129,"type":20},"2027-06",{"name":131,"class":44},"Mabwell (Shanghai) Bioscience Co., Ltd.",2,{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":141,"targetDuration":143,"studyType":21,"phases":4,"briefSummary":144,"conditions":145,"keywords":151,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":187},"100506479","utract-jelmyto-registry-a-registry-of-patients-with-upper-tract-urothelial-cancer-utuc-treated-with-jelmyto-100506479","NCT05874921","uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto","uTRACT Jelmyto Registry: A Multicenter, Prospective and Retrospective Registry to Evaluate Real World Experience and Outcomes of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto","uTRACT","Inclusion Criteria:\n\n* Adults \\>18 years old and capable of giving informed consent.\n* Diagnosis of UTUC.\n* Receipt of at least 1 dose of JELMYTO after FDA approval (15 Apr 2020).\n\nExclusion Criteria:\n\n* Incapable of giving informed consent (e.g., incarcerated individuals, individuals with dementia).\n* Receipt of 1 or more doses of JELMYTO (also referred to as UGN-101 or Mitogel in clinical development) before FDA approval (on or before 15 Apr 2020).\n* Pregnancy or lactation.\n* Unable to comply with protocol requirements (for prospective data capture).\n* Any medical or mental condition(s) that makes participation in the Registry inadvisable in the opinion of the Investigator (for prospective data capture).",{"count":142,"type":20},400,"3 Years","The purpose of this registry is to evaluate real world experience and outcomes of patients with Upper Tract Urothelial Cancer (UTUC) treated with Jelmyto in the United States.",[120,89,146,147,148,27,149,150],"Urothelial Carcinoma Ureter","Urothelial Carcinoma Ureter Recurrent","Urothelial Cancer of Renal Pelvis","Carcinoma, Transitional Cell","Transitional Cell Carcinoma of Renal Pelvis",[152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177],"Upper Tract Urothelial Cancer","UTUC","UGN-101","Mitomycin C","TCC","Ureteral","Upper Tract","Carcinoma","Kidney","Renal","Gel","Local","Prolonged Release","Slow Release","Kidney Sparing","Recurrence","Neoplasms by Histologic Type","Neoplasms","Urologic Neoplasms","Urogenital Neoplasms","Neoplasms by Site","Antibiotics, Antineoplastic","Antineoplastic Agents","Alkylating Agents","Nucleic Acid Synthesis Inhibitors","Enzyme Inhibitors","2025-02-25",{"date":180,"type":37},"2025-02-28",{"date":182,"type":37},"2023-11-17",{"date":184,"type":20},"2028-01",{"name":186,"class":44},"UroGen Pharma Ltd.",22,{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":4,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":194,"phases":4,"briefSummary":195,"conditions":196,"keywords":197,"overallStatus":201,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":202,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":203,"locationsCount":4},"100477242","named-patient-program-for-mitomycin-for-pyelocalyceal-solution-100477242","NCT05494411","Named Patient Program for Mitomycin for Pyelocalyceal Solution","Inclusion Criteria:\n\n* Patients who are suitable to receive JELMYTO and for whom there is reasonable expectation that JELMYTO may provide clinical benefit based on the medical judgment of their prescribing physician.","EXPANDED_ACCESS","This program provides controlled, pre-approval access to JELMYTO in response to unsolicited requests by physicians, hospitals, pharmacies, distributors, ministries of health or other parties on behalf of specific, or named patients, in select countries where JELMYTO has not yet received a marketing authorization and in situations when patients have exhausted all available treatment options.",[148,27,146,147,120,89],[198,199,154,200],"Low-grade Upper Tract Urothelial Cancer","LG-UTUC","Mitomycin","AVAILABLE",{"date":180,"type":37},{"name":186,"class":44},{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":210,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":214,"conditions":215,"keywords":216,"overallStatus":221,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":106},"100552412","neoadjuvant-radiotherapy-for-high-risk-utuc-100552412","NCT06472752","Neoadjuvant Radiotherapy for High-risk UTUC","Efficacy and Safety of Neoadjuvant Radiotherapy for High-risk Upper Tract Urothelial Carcinoma: A Single-arm, Open Label, Prospective Cohort Study","LUXUS07","Inclusion Criteria:\n\n·≥18 years old, no gender limits, diagnosed as high-risk UTUC without existing distant metastasis or other malignancies;\n\n* Completed pathological biopsy with a clear pathological diagnosis : including puncture biopsy, ureteroscopy and urine cytology, at least one of which is clearly diagnosed as uroepithelial carcinoma, which may include no more than 50% or more proportion of squamous, adenoid, sarcomatoid differentiation and other special differentiation types;\n* Have the willingness to undergo radical surgical treatment and perioperative adjuvant treatment, have good compliance, and be able to co-operate with the treatment and follow-up plan specified by the clinician;\n* Postoperative life expectancy of at least 6 months; ECOG score ≤ 2.\n\nExclusion Criteria:\n\n* Distant metastases or other malignant neoplastic diseases combined with other malignant neoplasms in the same period had been detected at the time of surgery, or the present was a progression after palliative resection of previous epithelial carcinoma of the urothelium;\n* History of pelvic and abdominal radiotherapy; history of inflammatory bowel disease; history of systemic chemotherapy;\n* Pregnant women or breastfeeding women; or women of childbearing potential who are not using reliable contraception;\n* The presence of active infections in those with pre-existing or coexisting haemorrhagic disorders\n* clinically significant cardiac disease (e.g., hypertension controlled with medications, unstable angina, New York Heart Association (NYHA) class ≥II congestive heart failure, unstable symptomatic arrhythmias, or class ≥II peripheral vascular disease);\n* Psychological, familial, and social factors leading to lack of informed consent.",{"count":213,"type":20},40,"The investigators propose to conduct an open-label, single-arm, prospective cohort study to collect and observe high-risk UTUC patients (with clear pathology of urothelial carcinoma and at least one of the following (muscle invasion \\[cT2 and above\\], high-grade tumour, multifocality, tumour diameter of ≥2cm, with hydronephrosis or regional lymph node metastasis) who undergo neoadjuvant therapy(neoadjuvant radiotherapy with\u002Fwithout drug) + radical nephroureterectomy. The cohort was evaluated by regular follow-up for safety and prognosis during the real-world neoadjuvant treatment period, perioperative period, and long-term postoperative follow-up.",[27],[217,153,218,219,220],"neoadjuvant radiotherapy","prospective cohort","microenviroment","neoadjuvant combined therapy","NOT_YET_RECRUITING","2024-06-23",{"date":224,"type":37},"2024-06-25",{"date":226,"type":20},"2024-06-30",{"date":228,"type":20},"2029-06-30",{"name":230,"class":72},"Peking University First Hospital"]